ClinicalTrials.gg
CompletedNCT01763710neurabraxUpdated Mar 29, 2016

Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer

A Phase 2 interventional study of Paclitaxel 80 mg/m2 and Nab-paclitaxel 100 mg/m2 days 1, 8 and 15 in Breast Cancer, sponsored by Fundacion Oncosur. Completed at 10 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-29.

Sponsored by Fundacion Oncosur · Phase 2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.

Enrollment
49th of 108
60 · median 60
Started
2012
with 7 others
Phase 2
67 of 108
9 open now
Registered
59th of 108
by date

Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 49th largest by enrollment, is one of 8 that started in 2012, is one of 67 in phase 2, and was the 59th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

Nanomedicines are currently being developed in the treatment of cancer due to their pharmacological advantages over traditional formulations; they provide a shorter infusion time and lower risks of hypersensitivity reactions associated with commonly used solvents.

Nab-paclitaxel is a nanoparticle albumin-bound particle form of paclitaxel that is thought to exploit natural albumin pathways to enhance the selective uptake and accumulation of paclitaxel at the site of the tumour, thus reducing its diffusion to normal tissues.

Nab-paclitaxel has been approved for the treatment of metastatic breast cancer patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.

SPARC is a cysteine rich acid protein that is overexpressed in a broad proportion of solid tumours. Expression of this protein could sensitize tumour cells to antitumor activity of Nab-paclitaxel, due to its union through albumin-binding to this protein.

First-line clinical trials have been developed with different Nab-paclitaxel regimens and also in combination with different chemotherapies and trastuzumab, showing a high level of efficacy.

Toxicity profile of Nab-paclitaxel is well characterized with significantly less haematological toxicities compared with conventional paclitaxel.

Nab-paclitaxel derived grade III neuropathy is short-lasting and more reversible than conventional paclitaxel-derived neuropathy, probably due to absence of Cremophor solvent, or due to paclitaxel itself.

However there is still a lack of clinical and physiological characterisation of Nab-paclitaxel induced neuropathy.

The current used tools for early detection and continuous evaluation of neurotoxicity are not optimal. Most used toxicity scales are limited, as they do not provide a detailed information of the severity of the neuropathy, its impact on quality of life, or physiopathology mechanisms.

In addition, an inter-individual variability exists in terms of neurotoxicity predisposition when taxanes are used; it could be related to polymorphic differences in genes implicated in transport and metabolism of these drugs.

03

Conditions studied

  • Breast Cancer

Keywords

  • Breast cancer
  • Neurotoxicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women with histologically or cytologically of stage IV breast cancer.
  2. Non-candidate patient to trastuzumab or lapatinib treatment as not presenting oncogene amplification.
  3. disease not previously treated with chemotherapy. It is allowed pre-treatment hormone with anti-target or bisphosphonates for advanced disease.
  4. Measurable or evaluable disease by criteria.
  5. Previous sensory neuropathy \<= grade 1, according to criteria, due to any reason.
  6. Age> 18 years.
  7. Performance status \<2 ().
  8. At least 12 months after the completion of chemotherapy with taxanes to diagnosis of metastatic disease.
  9. Creatinine \<= 1.5mg/dL, (SGOT), ALT (SGPT) and alkaline phosphatase \<= 2.5 x (hepatic metastases absent) in the 14 days prior to study entry.
  10. > 10g/dl, WBC> 3000/mm3, > 100000/mm3 and \<1.5 mg / dL in the 14 days prior to study entry.
  11. Women of with negative pregnancy test within 14 days prior to study treatment.
  12. Patients using adequate throughout the entire duration of the study and until 4 weeks after completion of treatment.
  13. At least 4 weeks after radiotherapy or major surgery, with complete recovery.
  14. greater than 12 weeks.
  15. Patients who are able to meet the requirements of the protocol.
  16. Patients able to provide with two plasma samples (each sample 5cc) for analyzing polymorphisms.
  17. Written .

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy treatment for disease.
  2. .
  3. Concomitant treatment with hormone therapy or immunotherapy for breast cancer, or during the two weeks prior to inclusion in the study.
  4. Any concomitant medical or psychiatric illness including active infection.
  5. History of any other than breast cancer in the past 5 years except carcinoma or basal cell skin carcinoma or carcinoma in situ of cervix.
  6. Prior treatment with an drug within the last 2 weeks.
  7. Known to paclitaxel or Cremophor.
  8. Pregnant or breastfeeding.
  9. Have any acute, subacute or chronic peripheral nerve or spinal cord in grade, at the time of inclusion, greater than or equal to 2 ( v4.0).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Arm A

    Paclitaxel 80 mg/m2 days 1, 8 and 15

    Drug: Paclitaxel 80 mg/m2

  • Experimental
    Arm B

    Nab-paclitaxel 100 mg/m2 days 1, 8 and 15

    Drug: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15

  • Experimental
    Arm C

    Nab-paclitaxel 150 mg/m2 days 1, 8 and 15

    Drug: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15

  • Experimental
    Arm D

    Nab-paclitaxel 150 mg/m2 days 1 and 15

    Drug: Nab-paclitaxel 150 mg/m2 days 1 and 15

Interventions

06

What researchers measure

Primary outcomes

  1. TNS - Total Neuropathy Score

    Time frame: Every 3 months up to 6 months

Secondary outcomes

  1. Evaluate the incidence of neuropathy induced by study treatment (conventional paclitaxel vs nab-paclitaxel)

    Time frame: Every 3 weeks up to 24 weeks

  2. Evaluate the electromyographic abnormalities and the correlation of these alterations with the assessment of the TNS scale and NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0

    Time frame: Every 12 weeks up to 24 weeks

  3. Determine the predictive value of genetic variants (SNPs) for the development of neuropathy

    Time frame: In the two weeks before start treatment

  4. Determine the clinical activity of both treatments (response rate, time to progression)

    Time frame: Every 8-12 weeks up to 24 weeks

  5. Determine toxicity profile and safety of study treatments (NCI-CTCAE v4.0)

    Time frame: Every 2 weeks up to 24 weeks

  6. Determine time to neurotoxicity onset

    Time frame: Every 2 weeks up to 24 weeks

  7. Determine time to recovery from neurotoxicity

    Time frame: Every 2 weeks up to 24 weeks

  8. Determine time to progression

    Time frame: Every 8-12 weeks up to 24 weeks

  9. Assess quality of live (EORTC QLQ-C30 and EORTC QLQ-CIPN20)

    Time frame: Every 4 weeks up to 24 weeks

07

Study locations

10 sites
  • Hospital Universitario Del Sureste
    Arganda del Rey, Madrid 28500, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitario de Getafe
    Getafe, Madrid 28905, Spain
  • Hospital Universitario Severo Ochoa
    Leganés, Madrid 28911, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Infanta Cristina
    Parla, Madrid 28981, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Hospital Ramón Y Cajal
    Madrid, 28034, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
08

References and documents

Publications

  • Ciruelos E, Apellaniz-Ruiz M, Cantos B, Martinez-Janez N, Bueno-Muino C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sepulveda JM. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. Oncologist. 2019 Nov;24(11):e1024-e1033. doi: 10.1634/theoncologist.2017-0664. Epub 2019 Apr 25. PubMed 31023863 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2012
First posted
Jan 9, 2013
Start
Dec 2012
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Mar 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01763710
Lead sponsor
Fundacion Oncosur
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
Dec 2012
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Mar 29, 2016

Study contacts

Eva Ciruelos, MD
study director · Hospital 12 de Octubre, Servicio de Oncología Médica
Noelia Martínez, MD
principal investigator · Hoapital Ramón y Cajal, Servicio de Oncología Médica
Rafael Carrión, MD
principal investigator · Hospital Universitario del Sureste, Servicio de Oncología Médica
José A García Sáenz, MD
principal investigator · Hospital Clínico San Carlos, Servicio de Oncología Médica
María Echarri, Md
principal investigator · Hospital Universitario Severo Ochoa, Servicio de Oncología Médica
Blanca Cantos, MD
principal investigator · Hospital Universitario Puerta de hierro Majadahonda, Servicio de Oncología Médica
Coralía Bueno, MD
principal investigator · Hospital Universitario Infanta Cristina, Servicio de Oncología Médica
Miguel A Lara, MD
principal investigator · Hospital Universitario Infanta Leonor
Santos Enrech, MD
principal investigator · Hospital Universitario de Getafe, Servicio de Oncología Médica
Juan A Guerra, MD
principal investigator · Hospital Universitario de Fuenlabrada

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion